A Safe Stimulant?

Stone, Andy
March 2006
Forbes Asia;3/13/2006, Vol. 2 Issue 4, p54
The article focuses on the late-stage trials of a modified version of the stimulant dextroamphetamine being conducted by New River Pharmaceuticals. Shire has purchased the rights to market the drug worldwide in 2005. If approved by the U.S. Food & Drug Administration, the modified drug could win a far less restrictive classification than traditional stimulants. It cites the benefits of the new drug to people with attention-deficit hyperactive disorder.


Related Articles

  • Shire: good days ahead for Daytrana.  // PharmaWatch: CNS;Jul2006, Vol. 5 Issue 7, p11 

    The article reports on the announcement of Shire PLC that its medical product Daytrana has demonstrated efficacy in reducing attention-deficit hyperactivity disorder (ADHD) symptoms. Daytrana is a transdermal methylphenidate delivery system which has been indicated for once-daily treatment of...

  • Shire Pharmaceuticals: astute move for New River.  // PharmaWatch: CNS;Apr2007, Vol. 6 Issue 4, p9 

    The article examines the plan of Shire Pharmaceuticals to acquire New River Pharmaceuticals for $2.6 billion. Last January 2005, Shire signed a collaborative agreement with New River for the development of attention-deficit hyperactivity disorder (ADHD) drug Vyvanse, a potential follow up to...

  • ADHD Update.  // PharmaWatch: CNS;Jan2006, Vol. 5 Issue 1, p13 

    The article presents news related to the treatment of attention deficit hyperactivity disorder (ADHD). The United States Food and Drug Administration's (FDA's) psychopharmacologic drugs advisory committee has voted Shire Pharmaceuticals' transdermal patch, Daytrana, as safe and effective for the...

  • Shire Pharmaceuticals: astute move for New River.  // PharmaWatch: Monthly Review;Apr2007, Vol. 6 Issue 4, p14 

    The article presents comments on Shire Pharmaceuticals Group PLC acquiring New River Pharmaceuticals Inc. It has been stated that New River's attention-deficit hyperactivity disorder (ADHD) drug, Vyvanse, is the reason for Sits acquisition. It is told that Shire's patent of its drug for ADHD,...

  • ADHD help in the form of a patch.  // Cortlandt Forum;Aug2006, Vol. 19 Issue 8, p21 

    The article provides information about Daytrana, a central nervous system stimulant, developed by Shire PLC in the U.S. The drug is indicated for use by patients with attention-deficit hyperactivity disorder. Daytrana is a matrix-type transdermal system that is designed to deliver...

  • ADHD Update.  // PharmaWatch: CNS;Apr2007, Vol. 6 Issue 4, p12 

    The article offers updates related to the treatment of attention-deficit hyperactivity disorder (ADHD) in the U.S. The Food and Drug Administration (FDA) has told manufacturers of ADHD drugs to develop medication guides. Shire and its partner New River Pharmaceuticals reported that the FDA has...

  • WALL STREET CHOICE: APPROVABLE LETTER PUT DRUG IN LINE WITH ADDERALL.  // Medical Marketing & Media;Nov2006, Vol. 41 Issue 11, p32 

    The article reports on the receipt of Shire Pharmaceuticals Group PLC and New River Pharmaceuticals Inc. of an approvable letter from the U.S. Food and Drug Administration concerning the marketing of its new attention-deficit hyperactivity disorder drug. The approval means that the drug will not...

  • Once-daily ADHD therapy.  // Cortlandt Forum;Aug2007, Vol. 20 Issue 8, p17 

    The article provides information on the central nervous system stimulant Vyvanse which is used in the treatment of Attention Deficit Hyperactivity Disorder (ADHD). It states that the drug is manufactured by Shire Pharmaceuticals Group PLC and is effective to children within the age limit of 6-12...

  • PSYCHIATRIC DISORDERS.  // MPR - Pharmacist's Edition;Fall2013, Vol. 7 Issue 3, p211 

    The article offers brief information on several drugs in treating attention-deficit hyperactivity disorder (ADHD) including the Kapvay central alpha-2 agonist from Shionogi & Co. Ltd., the Concerta stimulant from Janssen Pharmaceutica NV and the Daytrana stimulant from Noven Pharmaceuticals Inc.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics